Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

59.71 +0.61 (+1.03%)
Streaming Delayed Price Updated: 12:05 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutic

< Previous 1 2 3 4 5 6 7 Next >
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. 
Via Chartmill
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
Via Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. 
Via Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
Earnings Preview: Halozyme Therapeutics
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S. 
Via Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
NASDAQ:HALO: good value for what you're paying.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. 
Via Chartmill
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. 
Via InvestorPlace
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights. 
Via Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections 
Via Benzinga
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Healthcare stocks have underperformed in 2023, but that is expected to change this year. 
Via The Motley Fool
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.